Rigel Pharmaceuticals INC 10-Q quarterly reports

Rigel Pharmaceuticals announced significant revenue growth in the third quarter of 2025, driven by strong product sales across its commercial portfolio, despite the termination of a key CNS development program with Lilly.

Rigel Pharmaceuticals reported a significant turnaround in its second quarter, achieving substantial net income and revenue growth driven by robust product sales and a key collaboration payment.

Rigel Pharmaceuticals achieves profitability in Q1 2025, driven by increased sales of TAVALISSE, REZLIDHIA, and GAVRETO.

Rigel Pharmaceuticals saw a significant increase in revenue during the third quarter of 2024, primarily driven by strong product sales and collaboration revenue.

Rigel Pharmaceuticals' second quarter saw increased product sales offset by higher expenses, while the company advanced its pipeline with new collaborations and a key acquisition.

Rigel Pharmaceuticals' first quarter 2024 results show a revenue increase driven by REZLIDHIA sales, while TAVALISSE sales experienced a slight decrease.